VTGN - VistaGen Therapeutics Inc logo

VistaGen Therapeutics Inc

VTGN

VistaGen Therapeutics develops therapies for neuropsychiatric and neurological disorders, focusing on nasal spray candidates for anxiety, depression, and cognitive impairment, alongside oral treatments targeting brain receptors for mood disorders.

โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$2today

Score Overview

1 Year
Score
Net Growth2.96%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth97.16%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.3
Net Growth-41.58%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth125.63%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-4x
Net Trend40%
Net Income Consistency
Rev Growth100.16%
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-4x
Net Trend40%
Net Income Consistency
Rev Growth100.16%
Rev Trend60%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where VistaGen Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. VTGN does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-30
$ 0.31โ€”
1 Year2025-09-30
$ 3.55-91.33%
5 Years2021-09-30
$ 82.20-99.63%
10 Years2016-09-30
$ 126.90-99.76%
All Time2016-05-06
$ 210.00-99.85%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 2M-$ 67M$ 31M
2026$ 1M-$ 69M$ 45M
2025$ 486K-$ 51M$ 80M
2024$ 1M-$ 29M$ 119M
2023-$ 227.3K-$ 59M$ 16M
2022$ 1M-$ 47M$ 68M
2021$ 1M-$ 17M$ 103M
2020$ 334K-$ 20M$ 1M
2019$ 0.00-$ 24M$ 13M
2018$ 0.00-$ 14M$ 10M
2017$ 1M-$ 10M$ 2M
VTGN - VistaGen Therapeutics Inc logo

VistaGen Therapeutics Inc fundamental performance

Between 2021 and 2026, revenue grew from $ 1M to $ 1M and net income went from -$ 17M to -$ 69M. Revenue increased in 3 of those 5 years; net income in 2.

Between 2017 and 2026, revenue grew from $ 1M to $ 1M and net income went from -$ 10M to -$ 69M. Revenue increased in 60% of the years measured; net income in 40%.

VistaGen Therapeutics Inc currently holds a 5-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.

Membership

Explore VTGN with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies